Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > McWhirter on BNN Mentions Acasti

<< Previous

Bullboard Posts

Next >>

Comment by Canadian_101on Dec 28, 2019 7:45am

260 Views

Post# 30496375

RE:McWhirter on BNN Mentions Acasti

Thats to funny, on a number of episodes this year Robert has said his son wanted him to buy it big time but they did not own any, good to see he has picked up some shares......he is a very smart guy and just proved so once again!

Asset manager Robert McWhirter was on BNN today and was asked to comment on Acasti. He was confused about the phase of the clinical trial, said it was highly speculative but could go to $10 if the clinical trial was successful. He also owns it.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects